Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.

Abstract

In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conducted that reported on the efficacy of rFVIIa in reducing the amount of blood products transfused in blunt trauma patients. That study demonstrated the efficacy and safety profile of this hemostatic agent as compared with placebo as adjunctive therapy in the management of severe bleeding associated with trauma. Further prospective, randomized, and placebo-controlled clinical trials will yield more information on the role of rFVIIa in the management of traumatic bleeding.

• Authors: Alicia M Mohr, John B Holcomb, Richard P Dutton, Jacques Duranteau
• Journal: Critical care (London, England) (Crit Care) Vol. 9 Suppl 5 Pg. S37-42 ( 2005) ISSN: 1466-609X [Electronic] England
• PMID: 16221318 (Publication Type: Journal Article, Review)

Chemical References

• Recombinant Proteins
• Factor VII
• recombinant FVIIa
• Factor VIIa

Topics

• Blood Coagulation (drug effects)
• Disseminated Intravascular Coagulation (drug therapy)
• Factor VII (economics, pharmacokinetics, therapeutic use)
• Factor VIIa
• Half-Life
• Hemophilia A (drug therapy)
• Hemorrhage (drug therapy, etiology, surgery)
• Hemostasis (drug effects)
• Humans
• International Normalized Ratio
• Multicenter Studies as Topic
• Randomized Controlled Trials as Topic
• Recombinant Proteins (economics, pharmacokinetics, therapeutic use)
• Treatment Outcome
• Wounds and Injuries (drug therapy, mortality)